Table 1 NICE single technology appraisals of systemic therapies for psoriasis that include network meta-analyses
Psoriasis systemic therapy | Treatment class | Number of trials included in NMA | Sensitivity analyses undertaken |
|---|---|---|---|
Adalimumab (TA146, 2008) [7] | Anti-TNF-alpha | 18 randomised controlled trials (RCTs) | N/A |
Ustekinumab (TA180, 2009) [8] | Anti-IL-12/23 | 20 RCTs | N/A |
Secukinumab (TA350, 2015) [9] | Anti-IL-17 | 26 RCTs | Baseline PASI score; psoriasis duration; prior biologic therapy exposure; baseline Dermatology Life Quality Index (DLQI) score |
Apremilast (TA419, 2016) [10] | Anti-PDE4 | 22 RCTs | Prior biologic therapy exposure |
Ixekizumab (TA442, 2017) [11] | Anti-IL-17 | 40 RCTs | All treatment doses (base case included only NICE-approved doses) |
Dimethyl fumarate (TA475, 2017) [12] | Nrf2 activator | 37 RCTs | N/A |
Brodalumab (TA511, 2018) [4] | Anti-IL-17 | 59 RCTs | NICE-approved treatment doses; timing of primary outcome assessment; trial size; prior biologic therapy exposure; baseline PASI score |
Certolizumab pegol (TA574, 2019) [13] | Anti-TNF-alpha | 65 RCTs | Prior biologic therapy exposure |
Tildrakizumab (TA575, 2019) [14] | Anti-IL-23 | 45 RCTs | Timing of primary outcome assessment |